Effective adoptive T cell therapy requires the ex-vivo generation of functional T lymphocytes with a long lifespan in-vivo. We evaluated in-vitro T cell expansion by artificial antigen presenting cells (aAPC) generated with activating (human anti-CD3), co-stimulating (human anti-CD28) and adhesion (human anti-LFA-1) monoclonal antibodies pre-clustered in microdomains (MDs) held by a liposome scaffold. The co-localization of T cell ligands in MDs and the targeting of an adhesion protein, increasing the efficiency of immunological synapse formations, represent the novelties of our system. These aAPCs allowed increased expansion of polyclonal CD4+ and CD8+ T cells and of tumor antigen-specific CD8+ T cells compared to anti-CD28-and anti-CD3-coated microbeads and to immobilized anti-CD3. These aAPCs allowed the generation of T cells displaying an immunophenotype consistent with long-term in-vivo persistence, without increasing the frequency of regulatory T cells. Finally, our aAPCs proved to be suitable for large scale T cell expansion required in immunotherapy trials.
Introduction
The in vitro activation and expansion of antigen-specific T cells for therapeutic purposes has yielded impressive results in the context of prophylaxis and treatment of virus-associated infection and disease post-transplant 1, 2 . These successes prompted the extension of this method for the treatment of tumors in immunocompetent individuals 3, 4 , given the finding that antitumor specific T lymphocytes exist in cancer patients [5] [6] [7] , even if they are not able to overcome tumor immune escape mechanisms and to react efficiently against the tumor.
For clinical purposes, the use of natural antigen presenting cells (nAPCs), usually dendritic cells (DCs) or virally infected B cells, to activate and expand T cells for adoptive immunotherapy has been studied 8 , but still poses a lot of challenges. In particular, they require several months to produce sufficient numbers of T cells that may be a limiting factor in the setting of malignancy.
Moreover, after a long-term ex-vivo expansion, T cells are expected to have limited replicative capacity and persistence upon infusion into patients. Finally, the use of nAPC is limited by the difficulties in standardize protocols for their in-vitro generation, which, being highly sensitive to the culture conditions, is hardly reproducible 9 , and by the prerequisite for their application only in an autologous setting.
These evidences led to the production of artificial systems that express relevant molecules for T cell expansion. In this way, the functional activity of artificial APC can be modulated modifying the composition of the expressed molecules. Although several artificial systems have been produced [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , only the following systems are suitable for clinical use being generated under "Good
Manufacturing Practice" (GMP): immunomagnetic beads coated with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs) 22, 23 and anti-CD3 mAb immobilized on well bottom of culture plates. Even if these technologies are able to efficiently support the expansion of CD4 + T cells 24 , the long-term growth of purified CD8 + T cells 25 is hampered. More likely, the reason consists in a not efficient interaction of these systems with T cells 26, 27 , since they are not supplied with a fluid membrane, which makes it impossible for ligands to cluster and efficiently activate T cells.
The present work has been aimed at engineering an aAPC-based system with the properties of a fluid cellular membrane and the flexibility derived from an artificial structure, which can be properly tailored at the purpose. A stable interaction with APC for T cell activation is dependent not only on the absolute affinity between the T cell receptor (TCR) and its ligand but also on the relative density of relevant molecules at the interaction site. Furthermore, it has been recently shown that preclustering of MHC-peptide complexes in membrane MDs on the APC surface affects the efficiency of immune synapse formation and the related T cell activation 28, 29 . For these reasons, starting from aAPCs manufactured by Albani in which a liposomal formulation is loaded with class II HLA molecule-peptide complexes associated with costimulatory molecules, we modified aAPC by adding anti-CD3, instead of HLA molecule, and anti-LFA-1 adhesion molecule on MDs in lipidic bilayer to allow an efficient aAPC-T cell interaction.
We demonstrated that these aAPCs are able to expand more efficiently, compared to the other commercial artificial techniques, both viable and functional polyclonal T cells and antigen specific cytotoxic T lymphocytes (CTLs) with immunophenotypic characteristics that suggest a potential long-term persistence in vivo.
Materials and Methods

Generation of aAPC
For the preparation of aAPCs, the materials used by Albani et al. for the identification of rare antigen-specific T cells in autoimmune disorders [30] [31] [32] was made suitable for ex-vivo T cell activation and expansion with appropriate modifications. The resulting aAPCs consisted in a scaffold made of GM1 enriched-liposomes, which anchor microdomains (MDs) where mouse antihuman CD3, CD28
(BD PharMingen, San Diego, California) and LFA1 (Biodesign, Saco, Maine) triggering mAbs have been preclustered (Figure1A). At this end, biotinylated anti-CD3, anti-CD28 and anti-LFA1 mAbs were combined with biotinylated cholera toxin B (CTB; Sigma-Aldrich Inc.) in a 3:1 molar ratio for 5' at room temperature (RT), as previously described 30 . Therefore, neutravidin (NA; Pierce Biotechnology, Rockford, Illinois) was added at a ratio of 1 mol of NA per 4 biotinylated moieties.
After 15' of incubation at RT, the ganglioside GM1 enriched liposomes (gently provided by Dompè Biotec Spa, L'Aquila, Italy) were added. Liposomes were formed by detergent removal for 72 h through dialysis at 4°C against PBS in a 10K Slide A Lyzer (Pierce Biotechnology, Rockford IL).
After 90' of incubation while mixing, the aAPC solution was washed in PBS at 14000 rpm for 10'.
The pellet with aAPCs was resuspended in culture medium and used for T cell expansion. As controls, only the liposomial formulation (liposome alone) or the biotinylated mAbs on neutravidin rafts without liposomes (MD alone) were used in T cell cultures in the same conditions of complete aAPCs ( Figure 2 ). In order to corroborate the choice of the association of those three mAbs on aAPCs to achieve the best T cell expansion, initial experiments were performed using aAPC whose 35 . These cultures were carried on with the following combination of γ-chain cytokines accordingly to previous results 36 : i. low dose (LD) rhIL-2 (300U/ml, Proleukin, Chiron, Emeryville, California), ii.
Frequency of tetramer + T cells in the CD8
rhIL-15 (Peprotech Inc., Rocky Hill, New Jersey) 10 ng/ml, iii. high dose (HD) rhIL-2 (3000 U/ml) plus rhIL-15 10 ng/ml. Complete culture medium with cytokines was changed every 2 days during the 14 day-expansion with the artificial systems.
The aAPC stimulation: T cell ratio was reduced by diminishing mAb dose for the generation of aAPCs or by increasing the starting T cell amount in culture with aAPCs produced as previously described. In the first case, the biotinylated mAbs were added at 1/10 or 1/100 of the standard dose, resulting with biotinylated cholera toxin B and NA in 3/10 or 3/100: 1 molar ratio respectively.
These aAPCs were used for 14 day-expansion of 0.05 x 10 6 CD3 + purified T cells in association with HD IL-2 and IL-15 and they were compared to the standard ones in the same culture condition.
In addition, standard aAPCs were tested for the expansion of 10 or 100 fold increase number of starting T cell. Briefly, 0.5 x 10 6 or 5 x 10 6 CD3 + purified T cells were cultured in 1 or 4 ml of culture medium in 48 or 12 well plates respectively with standard aAPCs in the presence of HD IL-2 plus IL-15. Culture medium with cytokines was changed every 2 days during the 14 dayexpansions.
Flow cytometric analysis
Flow cytometric analysis of expanded T cells was performed on a FACSCalibur using the (mouse-antihuman APC-labeled CCR7 mAb, R&D systems, Minneapolis, Minnesota) mAb staining, were performed.
Cytotoxic assay
The cytotoxic activity of expanded specific MART-1 T cells was assessed through 51 Cr-release assay using as target Melan-A/MART-1 [27] [28] [29] [30] [31] [32] [33] [34] [35] 
Statistical analysis
Analysis of statistical significance were performed by using the Student's t test at the two-sided 0.05 significance level on Prism software (*: P≤ 0.05;**: P≤ 0.02; ***: P≤ 0.01).
Results aAPCs efficiently bind and expand human polyclonal T cells
As shown in Figure 1 MDs alone provided a positive stimulus for T cell proliferation, since they consisted of the biotinylated activating molecules grouped on NA, but putting them into a lipidic membrane allowed their activity to be efficiently oriented, raising the final stimulus for T cell expansion. Liposomes alone did not provide expanding stimulation for T cell cultures ( Figure 2 ).
aAPC stimulation enhance survival of human polyclonal T cells
Our aAPCs were compared with GMP systems (anti-CD3 and anti-CD28 coated immunomagnetic microbeads or immobilized anti-CD3) for the efficiency in expanding purified polyclonal CD3 + T cells. The cytokines reported above were added to T cell culture. Two weeks following the stimulation, the best methods resulted microbeads and aAPCs in combination with HD IL-2 plus IL-15 displaying comparable efficacy of polyclonal T cell expansion ( Figure 3A) . However, when apoptosis of expanded T cells was evaluated, aAPCs preserved the highest cell viability in culture compared to the other artificial systems ( Figure 3B ). In the bead-stimulated culture, only the 46% of expanded T cells was viable (annexin V-/propidium iodide-), whereas 83% of T cells were still alive 14 days after the stimulation with aAPCs that in turn displayed the statistically highest expansion ( Figure 3C ).
Immunophenotype of expanded polyclonal T cells
Fourteen days after stimulation, T cells displayed a naïve/effector phenotype, with a still evident In addition, when our aAPCs were used, CD8 + T cells were predominantly expanded, while CD4 + T cells were preserved at low level. On the contrary, anti-CD3/-CD28 microbead and immobilized anti-CD3 stimulation preferentially gave rise to CD4 + lymphocyte expansion ( Figure 4A-B) . 
Specific cytotoxic activity of efficiently expanded T cells by aAPCs is preserved
Since aAPCs rapidly activated and expanded polyclonal T lymphocytes, we have also tested aAPCs for the expansion of human anti-melanoma CTLs enriched for MART-1 specificity. MART-1 loaded HLA-A*0201 + TAP-deficient T2 cell line was used as APCs for anti-MART-1 specific TAL expansion, isolated from melanoma involved lymph nodes. After two culture weeks with the cognate peptide, they were aspecifically stimulated with aAPCs or immobilized anti-CD3 or with anti-CD3/-CD28 microbeads and expanded for additional 14 days in the presence of HD IL-2 and IL-15. As shown in Figure 5A , the highest expansion was obtained using aAPCs. In addition, anti-
MART-1 CD8
+ T lymphocytes stimulated with aAPCs preserved the closest specific cytolytic activity to the anti-MART-1 CD8 + enriched T cell grown with MART-1 pulsed-T2 cell line ( Figure   5B ). By contrast, while maintaining a highly pure anti-MART-1 CD8 + T cell population, the stimulation with the cognate antigen exhibited a limited expansion efficacy ( Figure 5A-B) . The aAPC trend in preferentially supporting the expansion of CD8 + T lymphocytes seen in polyclonal setting could reflect aAPC capability to preserve the specific activity of expanded anti-MART-1 specific CD8 + T cells that in turn might be responsible of the antitumor effect.
Moreover, the viability of aAPC expanded anti-MART-1 CD8 + T cells was preserved even in this setting ( Figure 5C ).
Immunophenotype of expanded anti-MART-1 CTLs
The immunophenotype of CD4 + and CD8 + T cells generated during the expansion of anti-MART-1
CTLs with aAPCs is shown Figure 6 that reported a representative FACScan analysis. The high positivity for CD62L expression in both CD8 + and the rare CD4 + T cells is consistent with in-vivo long-term persistence ( Figure 6 ). On the other hand, the widespread expression of CD69 suggested that the stimulation of aAPCs could activate specific CTLs as efficiently as polyclonal T cells ( Figure 6 ). In addition, after 14 culture days with aAPCs plus HD IL-2 and IL-15, the frequency of FoxP3 + regulatory T cells was not increased for both total CD8 + and anti-MART-1 specific CD8+ T cells, as well for the less frequent CD4 + T cells ( Figure 6 ).
Optimization of aAPC T cell expansion culture
In order to allow the feasibility of the procedure on large-scale for clinical application, several experiments have been performed reducing the dose aAPC stimulation or increasing the concentration of T cells in cultures. Diminishing to 1/10 or 1/100 the dose of biotinylated mAbs added to the aAPC mixture did not saturate the MDs, present on the liposome scaffold in the same number, saturated of stimulating molecules. These systems were less efficient than standard aAPCs in expanding the same number of starting T cells (data not shown). The best results were achieved when starting T cell number was increased of 10 or 100 fold ( Figure 7A ). Moreover, the maturation status and the potential capability of in vivo persistence, on the basis of CD62L expression, are preserved even on large-scale ( Figure 7B ). In addition, at 1:10 aAPCs: T cell ratio, 10 billion of antitumor T cells can be generated in a reduced volume with a limited cost, which makes this procedure suitable for clinical application ( Figure 7C ).
Discussion
In this report we demonstrate the advantages in T cell expansion conferred by a fully artificial system capable of mimicking nAPC membrane reorganization during immune synapse formation.
Our aAPCs exhibit high efficiency (1) To engineer our artificial system, we exploit the structure of the aAPCs developed by Albani S. et al. [30] [31] [32] By simply substituting the HLA-peptide complexes, which originally covered one site on Concurrently, a growing appreciation regarding lymphocyte characteristics that can impact on lymphocyte behavior in vivo is influencing the practice of ACT therapy. For instance, the discovery that the maturation status of CD8 + T lymphocytes determines their in vivo migration and persistence during an immune response [38] [39] [40] [41] [42] indicates new avenues for manipulating T cell activity.
These might include the alteration of in vitro T cell cultures to maintain a central memory phenotype 39 . Our work demonstrates that by associating aAPCs to HD IL-2 plus IL-15 it was possible to obtain the best expansion while generating T cells with a high expression of CD69, a marker associated with TCR engagement, and CD62L, a secondary lymphoid organ homing molecule. Moreover, our system was able to extensively arm expanded T cells with granzyme B, while reserving the capability to kill the target to a limited fraction of perforin + T cells, suggesting that, 14 days after stimulation, T cells were not terminal differentiated. Together these evidences suggest that part of expanded cells are acutely activated and could exert immediate effector functions upon in vivo infusion, but other cells retaining the capability to traffic through lymph-nodes, showing a naïve-memory phenotype, could be stimulated in vivo and then persist in the memory compartment 40 .
In addition, recent reports describing a requirement of CD4 + T cells for persistence of CD8 + T cells after an immune response underlines a potential role of CD4 + T cells in TIL cultures for ACT therapy [43] [44] [45] . Since cancers are for the most part weakly immunogenic and develop over long period of time, the presence of CD4 + T cells after ex-vivo expansion may be crucial for the effectiveness of ACT. Our aAPCs, while preferentially sustain the expansion of CD8 + T cells, exhibit a good activity even on CD4 + T cells. By contrast, the demonstration that CD4 + CD25 + regulatory T cells suppress autoimmunity and might be potent inhibitors of antitumor effects in mice indicates a rationale for additional investigation on lymphodepleting conditioning for ACT therapy 46, 47 . For these reasons, we evaluated the frequencies of CD4 + and CD8 + regulatory T cells defined as FoxP3 + and CD25 + in expanded cultures, and we found that they were kept at the lowest level when aAPCs were used. By contrast, using the other two systems, the amount of regulatory T cells was increased.
When aAPCs were assayed in pre-enriched MART-1 specific CD8 + T cell culture as aspecific stimulation, mimicking a possible program of anti-cancer immunotherapy, they highly efficiently generate the T cell population with the closest specific cytolytic activity to the same lymphocytes maintained in culture with MART-1 pulsed-T2, compared with antitumor CTLs expanded with microbeads or OKT3. Moreover, similarly to the expanded polyclonal T cell population, MART-1 specific CD8 + T cells cultured with our aAPCs still exhibit a central memory-naïve phenotype associated with a high expression of CD69, with no increase in regulatory T cell frequencies. Thus, previously enriched antigen specific CD8 + T cells can be efficiently expanded with aAPCs without any limitations due to HLA compatibility.
Because T cell expansion with aAPCs can be achieved with high efficiency even starting from a larger amount of T cells in a reduced volume limiting the costs for large-scale applications, it is likely that this system could have therapeutic potential in clinical setting for patients with cancer and viral diseases. In particular, using aAPCs to expand aspecifically the full T cell population of cancer patients, we envisage the possibility to increase the frequency of TAA specific lymphocytes which are usually represented at low level in the immune repertoire even after their initial amplification by boosting in vivo with specific vaccination 48, 40 . Moreover, in case of highly immunogenic tumors where TAAs are known and the related peptides available, it is possible to perform the aspecific expansion with aAPCs after the ex-vivo enrichment of antitumor specific
CTLs using in vitro co-cultivation with autologous tumor cells 49 . 
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